Amgen says that the combined data of two mid-stage trials demonstrate that its anemia drug Aranesp could help prevent hospitalization and death from heart failure. A large Phase III will be needed to validate the data. Report [1]
Links:
[1] http://today.reuters.com/stocks/QuoteCompanyNewsArticle.aspx?view=CN&storyID=2006-06-19T113121Z_01_WEN9664_RTRIDST_0_HEALTH-AMGEN-URGENT.XML&rpc=66